A fluorinated dendrimer-based nanotechnology platform: New contrast agents for high field imaging

Investigative Radiology

Volumn 45, Issue 10, 2010, Pages 641-654

  Huang, Zhihua ^a   Sengar, Raghvendra S ^a,b   Nigam, Archana ^a   Abadjian, Marie Caline ^c   Potter, Douglas M ^a,d   Grotjahn, Douglas B ^c   Wiener, Erik C ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c SAN DIEGO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

19F MRI; contrast agent; diffusion coefficient; fluorinated dendrimer; relaxation times

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CONTRAST MEDIUM; DENDRIMER; FLUORINE; FLUOROCARBON; GADOLINIUM; GADOTERIDOL; NANOPARTICLE; NEW DRUG;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; BIOCOMPATIBILITY; CARBON NUCLEAR MAGNETIC RESONANCE; CHELATION; COMPLEX FORMATION; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; FLUORINATION; FLUORINE NUCLEAR MAGNETIC RESONANCE; HIGH FIELD IMAGING; HYDRODYNAMICS; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTITION COEFFICIENT; PHANTOM; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SPECTROMETER; SURVIVAL; SYNTHESIS; TOXICITY TESTING;

EID: 77957252400     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181ee6e06     Document Type: Article

References (42)

1. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev. 1987;87:901-927.
2. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99: 2293-2352.
3. Aref M, Brechbiel M, Wiener EC. Identifying tumor vascular permeability heterogeneity with magnetic resonance imaging contrast agents. Invest Ra-diol. 2002;37:178-192.
4. Mandeville JB, Moore J, Chesler DA, et al. Dynamic liver imaging with iron oxide agents: effects of size and biodistribution on contrast. Magn Reson Med. 1997;37:885-890.
5. Billotey C, Wilhelm C, Devaud M, et al. Cell internalization of anionic maghemite nanoparticles: quantitative effect on magnetic resonance imaging. Magn Reson Med. 2003;49:646-654.
6. 1 contrast agents: accuracy, precision, and water exchange. Magn Reson Med. 1996;36:858-867.
7. Crich SG, Biancone L, Cantaluppi V, et al. Improved route for the visualization of stem cells labeled with a Gd-/Eu-chelate as dual (MRI and fluorescence) agent. Magn Reson Med. 2004;51:938-944.
8. 19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance. Curr Med Chem. 2005;12:819-848.
9. Schlemmer HP, Becker M, Bachert P, et al. Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res. 1999;59:2363-2369.
10. Wolf W, Presant CA, Waluch V. Non-invasive drug monitoring. Adv Drug Deliv Rev. 2000;41:55-74.
11. 31P nuclear magnetic resonance spectroscopy. Magn Reson Med. 1988;7:412-424.
12. 19F MRI probe to detect protease activity. J Am Chem Soc. 2008;130:794-795.
13. 19F MRI. Mol Imaging. 2006;4:330.
14. 19F MRI. Angew Chem Int Ed Engl. 2009;48:4755-4758.
15. Janjic JM, Srinivas M, Kadayakkara DK, et al. Self-delivering nanoemulsions for dual fluorine-19 MRI and fluorescence detection. J Am Chem Soc. 2008;130:2832-2841.
16. 19F nanoparticles. Magn Reson Med. 2004;52:1255-1262.
17. Caruthers SD, Neubauer AM, Hockett FD, et al. In vitro demonstration using 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla. Invest Radiol. 2006;41:305-312.
18. Ahrens ET, Flores R, Xu H, et al. In vivo imaging platform for tracking immunotherapeutic cells. Nature Biotech. 2005;23:983-987.
19. Waters EA, Chen J, Yang X, et al. Detection of targeted perfluorocarbon nanoparticle binding using 19F diffusion weighted MR spectroscopy. Magn Reson Med. 2008;60:1232-1236.
20. Tomalia DA, Naylor AM, Goddard WA. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Ed Engl. 1990;29:138-175.
21. Tomalia DA, Reyna LA Svenson S. Dendrimers as multi-purpose nanode-vices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans. 2007;35:61-67.
22. Grayson SM, Frechet JM. Convergent dendrons and dendrimers: from synthesis to applications. Chem Rev. 2001;101:3819-3868.
23. Lee CC, Mackay JA, Frechet JM, et al. Designing dendrimers for biological applications. Nat Biotech. 2005;23:1517-1526.
24. Helms B, Meijer EW. Chemistry: dendrimers at work. Science. 2006;313: 929-930.
25. Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today. 2001;6:427-436.
26. Svenson S, Tomalia DA. Dendrimers in biomedical applications\reflections on the field. Adv Drug Deliv Rev. 2005;57:2106-2129.
27. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818-1822.
28. Stiriba S, Frey H, Haag R. Dendritic polymers in biomedical applications: from potential to clinical use in diagnostics and therapy. Angew Chem Int Ed Engl. 2002;41:1329-1334.
29. Wiener EC, Brechbiel MW, Brothers H, et al. Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn Reson Med. 1994;31:1-8.
30. Wiener E, Narayanan VV. Advances in Dendritic Macromolecules. Vol.5. New York, NY: Elsevier; 2002:129-247.
31. Wiener EC, Konda S, Shadron A, et al. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Invest Radiol. 1997;32:748-754.
32. Hanessian S, Tehim A, Cheng P. Total synthesis of (-)- tetrahydrolipstatin. J Org Chem. 1993;58:7768-7781.
33. Dischino DD, Delaney EJ, Emswiler JE, et al. Synthesis of nonionic gadolinium chelates useful as contrast agents for magnetic resonance imaging: 1,4,7-tris (carboxymethyl)-10-substituted-1,4,7,10-tetraazacyclododecanes and their corresponding gadolinium chelates. Inorg Chem. 1991;30:1265-1269.
34. Platzek J, Blaszkiewicz P, Gries H, et al. Synthesis and structure of a new macrocyclic polyhydroxylated gadolinium chelate used as a contrast agent for magnetic resonance imaging. Inorg Chem. 1997;36:6086-6093.
35. Leo A, Hansch C, Elkins D. Partition coefficients and their uses. Chem Rev. 1971;71:525-616.
36. Moore DA. Metal complexes of tetraazamacrocycle derivatives. PCT Int Appl 2007, WO 2007106546. Publication date: 20 Sept 2007.
37. Xu J, Sun G, Rossin R, et al. Labeling of polymer nanostructures for medical imaging: importance of cross-linking extent, spacer length, and charge density. Macromolecules. 2007;40:2971-2973.
38. Lee H, Price RR, Holburn GE, et al. In vivo fluorine-19 MR imaging: relaxation enhancement with Gd-DTPA. J Magn Reson Imaging. 1994;4: 609-613.
39. 19F magnetic resonance imaging at 1.5 Tesla. Magn Reson Imaging. 1991;9:101-106.
40. Aime S, Fasano F, Paoletti S, et al. NMR relaxometric investigation on human methemoglobin and fluoromethemoglobin An improved quantitative in vitro assay of human methemoglobin. Magn Reson Med. 1995;33:827-831.
41. Laska EM, Meisner MJ. Testing whether an identified treatment is best. Biometrics. 1989;45:1139-1151.
42. Lide D. Handbook of Chemistry and Physics. 84th ed. Boca Raton, FL: CRC Press; 2003:16-43.